SCHEDULE: D. E. Shaw Discloses 9.5% Stake in Gossamer Bio

D. E. Shaw & Co. reports a 9.5% beneficial ownership stake in Gossamer Bio following a debt-for-equity exchange offer.

Summary

• D. E. Shaw & Co. and affiliated entities have disclosed a 9.5% beneficial ownership stake in Gossamer Bio, Inc. as of June 4, 2026.
• The stake was acquired primarily through an exchange offer where the firm surrendered $30.29 million in aggregate principal amount of existing 5.00% Convertible Senior Notes due 2027.
• In exchange, the firm received new 7.50% Convertible Senior Secured First Lien Notes due 2030, 48,107,644 new common shares, and 22,717,500 purchase warrants.
• The reporting persons have entered into voting agreements to support specific stockholder proposals, including an increase in authorized common shares and a potential reverse stock split.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-negative event for existing retail shareholders due to the massive dilution, though it is a positive step for the company's survival by avoiding immediate default.

Positives

• Successful completion of an exchange offer that significantly reduces the company's near-term debt burden by cancelling a majority of the 2027 convertible notes.
• Secured support from major noteholders for critical corporate governance and capital structure proposals.
• The new debt structure provides the company with a longer runway, with maturity extended to 2030.

Negatives

• Significant dilution to existing shareholders due to the issuance of over 254 million new common shares and additional warrants.
• The company is facing a potential reverse stock split, indicating concerns regarding share price levels and Nasdaq compliance.
• The new debt carries a higher interest rate of 7.50% compared to the previous 5.00%.

Risks

• The company's ability to satisfy obligations upon conversion of new notes is restricted until stockholder approval is obtained.
• Beneficial ownership limitations (4.99% to 9.99%) restrict the ability of major holders to convert notes or exercise warrants at will.
• The new notes have a 'springing maturity' date of March 2, 2027, if more than $4 million of the old notes remain outstanding.
• The company is dependent on the approval of multiple stockholder proposals to fully execute its capital restructuring plan.

Future Outlook

The company is seeking stockholder approval to increase authorized shares to 4 billion and implement a reverse stock split (1-for-10 to 1-for-150) to facilitate the conversion of new debt and warrants.

Management Comments

• The reporting persons intend to review their investment periodically and may increase or decrease their position based on market conditions.
• The reporting persons may engage in discussions with management regarding business strategy, capital structure, and corporate governance.

Industry Context

StockSavvy.ai notes that this transaction is a classic distressed debt-for-equity swap common in the biotech sector, where companies with limited cash flow must restructure balance sheets to avoid insolvency while heavily diluting existing equity holders.

Comparison to Industry Standards

• The use of 'springing maturity' clauses is a standard defensive mechanism in distressed debt restructurings to ensure full participation in exchange offers.
• The 9.99% ownership cap is a standard provision in private placements and debt conversions to avoid triggering 'change of control' provisions or regulatory scrutiny.

Corporate Governance

Legal Proceedings

• The reporting persons disclosed a 2023 SEC settled order regarding whistleblower protection language in employment agreements, which resulted in a $10 million penalty for D. E. Shaw & Co., L.P.

Related Party Transactions

• The reporting persons are investment advisers and managers for the funds that hold the securities, and Dr. David E. Shaw is the President and sole shareholder of the managing entities.

Stakeholder Impact

• Existing shareholders face significant dilution.
• Noteholders have exchanged debt for a combination of new debt, equity, and warrants.
• The company gains a more stable capital structure to continue operations.

Next Steps

• Hold the Special Meeting of stockholders on July 14, 2026.
• Seek approval for the Restated Incentive Award Plan and the increase in authorized common shares.
• Determine the final ratio for the reverse stock split.

Key Dates

Recommendation

The company is in a high-risk restructuring phase. While the debt exchange prevents immediate insolvency, the massive dilution and pending reverse stock split create significant uncertainty for equity valuation.

Keywords

Gossamer Bio, D. E. Shaw, Schedule 13D, Convertible Notes, Debt Restructuring, Exchange Offer, Equity Dilution